Syndax Pharmaceuticals, Inc.
NASDAQ: SNDX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael A. Metzger
- Employees
- 270
- Headquarters
- New York City, United States
- IPO year
- 2016
- Market cap
- $1.8B
- Website
- https://www.syndax.com
Loading SNDX…
Loading profile data…Frequently asked questions about SNDX
What does Syndax Pharmaceuticals, Inc. (SNDX) do?
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLL...
Where does SNDX trade?
Syndax Pharmaceuticals, Inc. (SNDX) trades on the NASDAQ Global Select.
What sector is SNDX in?
Syndax Pharmaceuticals, Inc. (SNDX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Syndax Pharmaceuticals, Inc.?
Michael A. Metzger is the chief executive officer of Syndax Pharmaceuticals, Inc. (SNDX).
Where is Syndax Pharmaceuticals, Inc. headquartered?
Syndax Pharmaceuticals, Inc. is headquartered in United States.
Does SNDX pay a dividend?
Syndax Pharmaceuticals, Inc. (SNDX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SNDX go public?
Syndax Pharmaceuticals, Inc. (SNDX) completed its initial public offering in 2016.